Abstract 191P
Background
Gastric cancer (GC) is a major global health concern, with prognosis influenced by tumor stage and its microenvironment, especially immune cell presence. This research investigates the relation between CD8 T cell expression, emphasizing CXCR6, and GC survival outcomes.
Methods
Using TCGA-STAD RNA-seq data, we studied a cohort of 280 Stage 2 and 3 GC patients. CD8 T cell expression was examined through X Cell Analysis, followed by Cutoff Determination via R package Maxstat. Post categorization into CD8L and CD8H groups, Differential Gene Expression Analysis identified 495 upregulated and 102 downregulated genes. Weighted Gene Co-expression Network Analysis highlighted CXCR6's importance. Correlations between CXCR6, immune cell infiltration, and survival patterns were explored. Verification came from GES 62254 data and Immunohistochemical Staining of a sample from Dong-A University Hospital.
Results
The findings reveal that heightened CXCR6 expression is significantly associated with improved survival outcomes in both recurrence-free survival (RFS) and overall survival (OS) using TCGA-STAD data. Importantly, the validation using GES 62254 data consistently supports these results. Moreover, the study delves into the tumor microenvironment using TCGA-STAD RNA-seq data, showcasing a positive link between CXCR6 expression and immune cell presence, particularly CD8 T cells, T cell gamma delta cells, NK cells, and activated DCs. This suggests a potential reinforcement of anti-tumor responses. The research further uncovers correlations between CXCR6 expression and markers of CD8 T cell activation, as well as the activation of DCs.Importantly, a clinical investigation involving GC patients treated at Dong-A University Hospital supports the statistical significance of increased CXCR6 expression in relation to enhanced survival rates.
Conclusions
Our research showcases the relationship between enhanced CXCR6 expression and improved GC patient survival. It presents CXCR6 as a potential prognostic biomarker, underscoring its role in the tumor immune milieu. The focus on CD8 T cells and immune pathways suggests promising therapeutic directions, marking a step toward precision-based GC interventions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
National foundation of Korea grant.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract